Silver Sulfadiazine Market Analysis
Silver Sulfadiazine Market – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Silver sulfadiazine is specifically used for second degree or third-degree burns on the skin, which acts ant-bacterial drug. The World Health Organization considers silver sulfadiazine as an Essential Medicines and is used as an antibiotic for skin burns. Silver sulfadiazine helps to prevent growth of yeast and bacteria and is used to treat urinary tract infections (UTI). When it is combined with pyrimethamine, the combination is used for the treatment of toxoplasmosis. Furthermore, a typical anti burn cream 1% of silver sulfadiazine contains, which is crucial to maintain as excessive quantity would make it toxic. However, some organizations do not recommend its use, as it has been a subject of research and various speculation. Moreover, there have been some side effects of silver sulfadiazine such as loss of appetite, dizziness, and nausea.
Global silver sulfadiazine market size is expected to increase significantly during to forecast period (2019-2027). Burn injuries are considered severe healthcare problems and far more serious than other epidemics such as polio. According to the World Health Organization, around 180,000 deaths occur due to burns, majorly in emerging economies. Furthermore, non-fatal burn injuries are the leading cause of morbidity. This is expected to increase the demand for anti-burn creams and lotions and subsequently drive the market growth. Furthermore, silver sulfadiazine has been majorly used hospitals in North America as it is considered as a powerful treatment for burns.
However, silver sulfadiazine causes minor side effects such as nausea, loss of appetite, and dizziness, which may hinder the demand for the product and subsequently restrain the global silver sulfadiazine market growth. Furthermore, increasing the price of silver, which is one of the prime raw materials for the production of silver sulfadiazine expected to hinder
North America is expected to account for the largest market share in the global silver sulfadiazine market, during the forecast period. This is owing to increased burn cases and increasing demand for wound-care products. According to the National Fire Protection Association (NFPA), around every two hours, a civilian die from fire outbreaks, which has increased the demand for wound-care products. Furthermore, increasing government initiatives to fund research and development of medicines to treat burn wounds has accelerated the market growth. Moreover, Asia Pacific is expected to witness significant growth in the market, owing to increasing demand for silver sulfadiazine from emerging economies such as India and China. The countries Australia, China, and India are expected to emerge as new revenue generators in the region.
Key players operating in the global silver sulfadiazine market include 3M Company, Baxter International, Inc., Monarch Pharmaceuticals, Teva Pharmaceutical Industries Ltd, and Johnson & Johnson Limited.